Oyster Point Pharma to Report Third Quarter 2021 Financial Results on November 4, 2021
Oyster Point Pharma (Nasdaq: OYST) will announce its third quarter 2021 financial results on November 4, 2021, after market close. Following this announcement, a live audio webcast and conference call will occur at 4:30 p.m. ET. The company recently received FDA-approval for TYRVAYA™ (varenicline solution) Nasal Spray, targeting dry eye disease, impacting approximately 38 million people in the U.S. This approval marks a key milestone in its drug development strategy to address unmet needs in ophthalmic treatment.
- FDA approval for TYRVAYA™ nasal spray for dry eye disease enhances product portfolio.
- Growing pipeline of clinical and pre-clinical programs may lead to future growth opportunities.
- None.
Conference Call and Webcast Scheduled for November 4, 2021, 4:30 p.m. Eastern Time
PRINCETON, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it will report third quarter 2021 financial results on Thursday, November 4, 2021, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 p.m. Eastern Time.
Conference Call Details
To access the live call by phone, please dial (855) 548-1220 (US/Canada) or (602) 563-8619 (International). The conference ID number is 4538958. A telephone replay will be available for approximately 7 days following the live conference call. To access the telephone replay, please dial (855) 859-2056 (US/Canada) or (404) 537-3406 (International). The conference ID number is 4538958.
Webcast Details
The webcast will be made available on the company’s website at www.oysterpointrx.com under the “Events & Presentations” section.
About Oyster Point Pharma, Inc.
Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. In October 2021, Oyster Point Pharma received FDA-approval for TYRVAYA™ (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease. Oyster Point has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations. Oyster Point is continuously striving to advance breakthrough science and deliver therapies seeking to address the unmet needs of patients with ophthalmic disease and the eye care professionals who take care of them. For more information, visit www.oysterpointrx.com and follow @OysterPointRx on Twitter and LinkedIn.
About Dry Eye Disease and the Role of Tear Film
Dry eye disease is a chronic condition that impacts an estimated 38 million people in the U.S. and is growing in prevalence. It can cause persistent stinging, scratching, burning sensations, sensitivity to light, blurred vision, and eye fatigue. Dry eye disease is a multifactorial disease of the ocular surface characterized by disruption of the tear film. Human tear film is a complex mixture of more than 1,500 different proteins, including growth factors and antibodies, as well as numerous classes of lipids and mucins. Natural tear film protects and lubricates the eyes, washes away foreign particles, contains growth factors and antimicrobial components, and creates a smooth surface that forms the primary refractive surface of the eye.
Investor Contact:
Tim McCarthy
LifeSci Advisors, LLC
(212) 915-2564
investors@oysterpointrx.com
Media Contact:
Sheryl Seapy, Real Chemistry
(213) 262-9390
sseapy@realchemistry.com
FAQ
When will Oyster Point Pharma announce its Q3 2021 financial results?
What is the conference call number for Oyster Point Pharma's Q3 2021 earnings?
What recent approval did Oyster Point Pharma receive?
What is the significance of the drug TYRVAYA™?
